Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
16.08 USD | +3.77% | -0.12% | +7.86% |
Apr. 18 | Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing | MT |
Apr. 10 | ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.86% | 783M | |
-1.42% | 105B | |
+3.38% | 97.5B | |
+1.86% | 22.19B | |
-16.30% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.22% | 14.52B | |
+4.93% | 14.09B | |
+28.78% | 10.99B |
- Stock Market
- Equities
- ALXO Stock
- News ALX Oncology Holdings Inc.
- ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial